Please login to the form below

Not currently logged in
Email:
Password:

Achillion

This page shows the latest Achillion news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The $6.30-per-share offer is a 73% premium on Achillion’s closing share

Latest news

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    J&J is also continuing to research new HCV therapies, and earlier this year paid up to $1.1bn for the rights to Achillion Pharmaceuticals' pipeline of drugs, headed by

  • J&J signs $1bn deal with Achillion for hepatitis C therapies J&J signs $1bn deal with Achillion for hepatitis C therapies

    Will license three candidates from Achillion Pharma.  . Johnson &Johnson (J&J) has fleshed outs its portfolio of hepatitis C virus drugs, licensing three candidates from Achillion Pharma in a deal valued ... The agreement - which sits alongside a $225m

  • Gilead and Achillion see 100% success rate in hep C trial Gilead and Achillion see 100% success rate in hep C trial

    Gilead and Achillion have posted impressive clinical study results for a new all-oral combination hepatitis C treatment. . ... be an all-Achillion regimen, predicted to hit the US market by the end of the decade.

  • Hepatitis C therapies: dawn of a new age Hepatitis C therapies: dawn of a new age

    Achillion Pharmaceuticals has DAAs sovaprevir, neceprevir and ACH 3102 in the works, Idenix and Janssen are collaborating on samatasvir and TMC 647055, and phase 2 development of JNJ 56914845 (Janssen) is

  • FDA forces Achillion to delay hepatitis C programme FDA forces Achillion to delay hepatitis C programme

    Abnormal liver functions detected in some patients taking sovaprevir. Achillion's development of its hepatitis C treatment sovaprevir will be delayed after reports of abnormal liver functions in some patients caused ... trials. According to Achillion,

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Pharma deals in May 2015 Pharma deals in May 2015

    Clearly a very successful and creative partnership! Choosing to opt for partnership over an acquisition, J&J closed a multiple licence with Achillion to build on its hepatitis C portfolio. ... 1, 300. Achillion/ J&J. Licence. Joint development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics